Sort
16,300 grants matching “fatty liver disease”
Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism
$808,590Byoung-Joon Song · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2014 · AA
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
$808,231Rajagopal Viswanath Sekhar · Baylor College Of Medicine · R01 · FY2020 · AG
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
$808,164Jay W Heinecke · University Of Washington · R01 · FY2025 · HL
The Gut Microbiota and Graft versus Host Disease (GVHD)
$808,150David Neal Fredricks · Fred Hutchinson Cancer Research Center · R01 · FY2020 · AI
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
$808,114Takara Leah Stanley · Massachusetts General Hospital · R01 · FY2019 · DK
SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques
$808,058Ivona Pandrea · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · HL
Longitudinal integration of environmental exposures, omics, and childhood NAFLD (LEON) Study
$807,798Vaia Lida Chatzi · University Of Southern California · U01 · FY2023 · HG
Dietary treatment of Glucose Transporter Type 1 Deficiency (G1D)
$807,752Juan M. Pascual · Ut Southwestern Medical Center · R01 · FY2017 · NS
Toward Diagnostics and Therapies of Molecular Subcategories of CAD
$807,678Johan M Bjorkegren · Icahn School Of Medicine At Mount Sinai · R01 · FY2016 · HL
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
$807,629Takara Leah Stanley · Massachusetts General Hospital · R01 · FY2020 · DK
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
$807,629Takara Leah Stanley · Massachusetts General Hospital · R01 · FY2022 · DK
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
$807,629Takara Leah Stanley · Massachusetts General Hospital · R01 · FY2021 · DK
Clinical Research on Nonalcoholic Fatty Liver Disease
$807,150Joel Edward Lavine · Columbia University Health Sciences · U01 · FY2013 · DK
General Clinical Research Center
$806,732Sheldon M Retchin · Virginia Commonwealth University · M01 · FY2010 · RR
Hepatic insulin resistance integrates T2D and NAFLD
$806,452Morris F. White · Boston Children'S Hospital · R01 · FY2024 · DK
Genetic and environmental contributions to obesity pathogenesis
$805,464Ellen A Schur · University Of Washington · R01 · FY2025 · DK
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity
$805,342Wanpen Vongpatanasin · Ut Southwestern Medical Center · R01 · FY2022 · HL
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity
$805,268Wanpen Vongpatanasin · Ut Southwestern Medical Center · R01 · FY2023 · HL
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity
$805,115Wanpen Vongpatanasin · Ut Southwestern Medical Center · R01 · FY2025 · HL
Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism
$804,378Byoung-Joon Song · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2019 · AA
Metabolic Actions of Glucagon
$804,342Jonathan E Campbell · Duke University · R01 · FY2025 · DK
Tissue-Specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia
$804,137Jean-Marc Schwarz · University Of California, San Francisco · R01 · FY2022 · DK
Tissue-Specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia
$803,867Jean-Marc Schwarz · University Of California, San Francisco · R01 · FY2023 · DK
Discovery of Pharmacogenomic Biomarkers for Metformin Response
$803,285Kathleen M Giacomini · University Of California, San Francisco · R01 · FY2016 · GM
Toward Diagnostics and Therapies of Molecular Subcategories of CAD
$802,881Johan M Bjorkegren · Icahn School Of Medicine At Mount Sinai · R01 · FY2017 · HL